NPPB and pulmonary arterial hypertension: The Phase 3 STELLAR clinical trial showed that sotatercept increases exercise capacity (6-min walk distance), improves WHO functional class and NT-proBNP levels, and reduces the risk of clinical worsening events in PAH patients [2].